Treatment of myelodysplastic syndrome: questions raised by the azacitidine experience.
Kantarjian
Hagop M
HM
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001374:Azacitidine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D012074:Remission Induction; D012307:Risk Factors; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine